Evidence for improvement in survival with antihypertensive combination treatment

Journal of Hypertension

Volumn 29, Issue SUPPL. 1, 2011, Pages

  Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antihypertensive treatment; Combination therapy; Outcome trials; Survival

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

EID: 83655196774     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/01.hjh.0000410247.97338.e7     Document Type: Review

References (52)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223. (Pubitemid 40138015)
2. Martiniuk AL, Lee CM, Lawes CM, Ueshima H, Suh I, Lam TH, et al. Woodward M, for the Asia-Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007;25:73-79. (Pubitemid 44885666)
3. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-2369. (Pubitemid 37430168)
4. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774. (Pubitemid 20106689)
5. British Heart Foundation. European cardiovascular disease statistics, British Heart Foundation 2000. available on www.dphpc.ox.ac/UKbhfhprg.
6. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-1576. (Pubitemid 26154243)
7. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562. (Pubitemid 26154241)
8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18. (Pubitemid 26012498)
10. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
11. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-1360. (Pubitemid 35341298)
12. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
13. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reapparaisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158.
14. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 1995;26:60-69.
15. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003;21:1199-1205. (Pubitemid 36667875)
16. Mancia G, Ambrosioni E, Agabiti-Rosei E, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005;23:1575-1581. (Pubitemid 41104830)
17. NCHS Data Brief, October 2010 No. 48. available on http://www.cdc.gov/ nchs/data/databriefs.
18. Wagner A, Sadoun A, Dallongeville J, Ferrières J, Amouyel P, Ruidavets JB, Arveiler D. High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study. J Hypertens 2011;29:43-50.
19. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008;28(11):713-734.
20. Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Clin Hypertens (Greenwich) 2003;5 (4 Suppl 3):12-20.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
22. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11, 000 participants from 42 trials. Am J Med 2009;122:290-300.
23. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163(5):525-541. (Pubitemid 36314340)
24. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004;17:37-42. (Pubitemid 38064757)
25. Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: A review of the evidence. Am J Health Syst Pharm 2010;67:885-894.
26. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031. (Pubitemid 38781102)
27. MacMahon S, Neal B, Tzourio C, Rodgers A, Woodward M, Cutler J, et al., on behalf of the PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041. (Pubitemid 32925123)
28. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al., on behalf of the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-840. (Pubitemid 47362321)
29. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al., for the HYVET Study Group. Treatment ofhypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. (Pubitemid 351620109)
30. Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension. Drugs 2000;59(Suppl 2):27-38. (Pubitemid 30092981)
31. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens 2006;19:113-121. (Pubitemid 43217045)
32. Hansson L. Concluding remarks. Pursuit of the optimal outcome in hypertension. Clin Pharmacokinet 1999;37(Suppl 1):33-38. (Pubitemid 29419547)
33. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol 2005;19:637-645. (Pubitemid 43821998)
34. Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs 2006;66:257-271. (Pubitemid 43213906)
35. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol 2011;57:590-600.
36. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
37. Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009;32:51-58.
38. Sanford M, Keam SJ. Olmesartan medoxomil/amlodipine. Drugs 2009;69:717-729.
39. Flack JM, Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. Expert Opin Pharmacother 2009;10:1979-1994.
40. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al., for The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764. (Pubitemid 27387202)
41. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998;16:1823-1829. (Pubitemid 28548522)
42. Hansson L, Zanchetti A, Carruthers SG, Dalhöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
43. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, for the ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
44. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
45. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al., ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.
46. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al., INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816. (Pubitemid 37509488)
47. Fox KM, Bertrand M, Ferrari R, Remme WJ, Simoons ML, for the European trial on reduction of cardiac events with perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788. (Pubitemid 37093919)
48. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction: may they rest in PEACE? N Engl J Med 2004;351:2115-2117. (Pubitemid 39482506)
49. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., on behalf of the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
50. Yusuf S, Sleight P, Anderson C, Teo K, Copland I, Ramos E, et al., on behalf of the ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. (Pubitemid 351522739)
51. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-553.
52. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al., for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1896.